Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AgeX Therapeutics, Inc.

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Announces Appeal of NYSE American Determination
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports First Quarter 2023 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports Second Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports First Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports Third Quarter 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
From AgeX Therapeutics, Inc.
Via Business Wire
Tickers AGE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.